Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma

Area of Science:

• Hepatocellular Carcinoma (HCC) research
• Inflammatory markers in oncology
• Prognostic factor analysis

Background:

• Circulating inflammatory factors play a role in hepatocellular carcinoma (HCC) development and prognosis.
• Existing inflammation-based indices (IBI) for HCC require refinement.
• Objective inflammatory scoring is needed for HCC prognostication.

Purpose of the Study:

• To evaluate the prognostic value of multiple serum inflammatory factors in HCC.
• To develop an objective inflammatory score for HCC patients.
• To create a modified inflammation-based index (IBI) for improved HCC prognostication.

Main Methods:

• Prospective cohort study of 555 HCC patients.
• Measurement of conventional (CRP, albumin, neutrophils, lymphocytes, platelets) and 41 exploratory inflammatory markers.
• Univariate and multivariate analyses to determine prognostic factors and interactions.

Main Results:

• Higher C-reactive protein (CRP), lower albumin, and higher interleukin-8 were independent prognosticators for overall survival in HCC.
• A modified IBI, including serum interleukin-8, stratified patients into four distinct survival groups.
• The modified IBI demonstrated superior prognostic performance compared to the original IBI and other conventional markers in both training and validation cohorts.

Conclusions:

• CRP, albumin, and interleukin-8 are key circulating inflammatory markers for HCC prognostication.
• A simple and accurate inflammatory index can be constructed by combining these key factors.
• The modified IBI offers enhanced prognostic capability for hepatocellular carcinoma.